Liposarcoma - Pipeline Insight, 2025

This “Liposarcoma - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Liposarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Liposarcoma: Understanding

Liposarcoma: Overview

Liposarcoma is a rare and heterogeneous group of malignant tumors that arise from adipose (fat) tissue, representing approximately 13-20% of all soft tissue sarcomas. It is categorized into four subtypes based on histological characteristics: well-differentiated liposarcoma (WDLS) or atypical lipomatous tumor (ALT), dedifferentiated liposarcoma (DDLS), myxoid liposarcoma (MLS), and pleomorphic liposarcoma (PLS), with WDLS/ALT being the most common. Due to its rarity and complex nature, liposarcoma diagnosis can be challenging, often leading to misdiagnosis in up to 30% of cases. This diagnostic difficulty, along with limited treatment options, highlights the need for continued research and improved clinical strategies to enhance early detection and therapeutic outcomes for patients. Current treatment modalities include surgery, radiation therapy, and chemotherapy, though the prognosis remains variable depending on the subtype and stage of disease. Early detection and accurate diagnosis are critical for improving patient outcomes and survival rates.

Liposarcomas often present without noticeable symptoms, but a visible lump may develop under the skin, typically painless in the early stages. Clear warning signs include the appearance of a new lump or the persistent growth of an existing one, pain or numbness around the lump, and signs of internal bleeding, such as blood in the stool or vomit. Symptoms can vary depending on the location of the tumor. In the limbs, liposarcomas may cause a growing mass, pain, swelling, and weakness in the affected limb. When located in the abdomen, they may lead to abdominal pain, swelling, early satiety, constipation, and blood in the stool. As the tumor grows, it may press on surrounding tissues, further causing discomfort and impairment in function, which can lead to more noticeable symptoms. Early detection is crucial for better management and treatment outcomes.

The exact cause of liposarcoma remains unclear, but it is believed to result from genetic changes in fat cells' DNA. These changes cause the cells to transform into cancerous cells, leading to uncontrolled growth and division. The altered DNA prevents these cancer cells from dying as healthy cells would in their normal life cycle. In some cases, the cancerous cells remain localized, forming a tumor that grows larger over time. However, in other types of liposarcoma, the cancer cells can break away from the original tumor and spread to other parts of the body, a process known as metastasis. While specific risk factors are not fully understood, exposure to radiation, certain genetic conditions, and long-term exposure to toxic chemicals are thought to increase the risk of developing liposarcoma.

To diagnose liposarcoma, doctors typically start with a biopsy, which involves removing a sample of suspicious tissue either through a needle or during surgery. A pathologist examines the tissue under a microscope to check for cancer cells. If liposarcoma is confirmed, additional imaging tests such as X-rays, MRI, CT scans, or ultrasound may be ordered to assess the size of the tumor and determine how far the cancer has spread. In some cases, a PET scan may also be used. The biopsy sample is sent to a laboratory for further analysis, allowing doctors to better understand the cancer's characteristics, prognosis, and to help plan appropriate treatment.

Treatment for liposarcoma typically begins with surgery to remove the tumor, with the goal of excising all cancerous cells while preserving surrounding organs. In cases where the tumor involves nearby organs, other treatments like radiation or chemotherapy may be used to shrink the tumor before surgery, making it easier to remove. Radiation therapy uses high-energy beams to kill cancer cells and may be employed both before and after surgery to target remaining cancer cells. Chemotherapy, which uses powerful drugs to kill cancer cells, is not effective for all types of liposarcoma but may be used in combination with surgery or radiation to treat the cancer. The treatment plan is tailored to the specific characteristics of the tumor and the patient’s condition.

'Liposarcoma- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Liposarcoma pipeline landscape is provided which includes the disease overview and Liposarcoma treatment guidelines. The assessment part of the report embraces, in depth Liposarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Liposarcoma.

Liposarcoma Emerging Drugs Chapters

This segment of the Liposarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Liposarcoma Emerging Drugs

Brigimadlin: Boehringer Ingelheim

Brigimadlin is a potent, oral MDM2-p53 antagonist. Brigimadlin binds to MDM2 and blocks the MDM2-p53 interaction which prevents MDM2 from inactivating p53, thereby restoring p53 function. The MDM2 oncoprotein is a critical regulator of the tumor suppressor p53. Overexpression of MDM2 promotes p53 degradation and aids tumor proliferation. Preclinical study results have shown that brigimadlin had single-agent efficacy in MDM2-amplified DDLPS PDX models and improved responses/disease control in patient-derived xenografts and syngeneic mouse tumor models. Currently, the drug is in Phase III stage of its development for the treatment of Liposarcoma.

APG-115: Ascentage Pharma Group Inc.

APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. APG-115 has strong binding affinity to MDM2 and is designed to activate p53 tumor suppression activity by blocking the MDM2-p53 PPI. Preclinical studies demonstrated that APG-115 promoted the production of proinflammatory cytokines in T cells, enhanced CD4+ T cell activation, and increased PD-L1 expression on various tumor cells. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Liposarcoma.

CAR-GPC3 T Cells: Sotio Biotech Inc.

CAR-GPC3 T Cells, uniquely combine the GOT2 transgene of the proprietary BOXR platform, a critical enzyme involved in cellular metabolism, with CAR T technology targeting GPC3-expressing tumors. BOXR1030 is a next generation CAR T cell therapy which benefits from its enhanced T cell metabolism in the solid tumor microenvironment. CAR-GPC3 T Cells have demonstrated strong preclinical evidence in models that simulated the solid tumor microenvironment. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Liposarcoma.

BTX-A51: Edgewood Oncology Inc.

BTX-A51 is a first-in-class, small molecule, multi-kinase inhibitor of casein kinase 1 alpha (CK1α), cyclin-dependent kinase 7 (CDK7) and CDK9 that synergistically co-targets master regulators of cancer to promote programmed cell death, or apoptosis. BTX-A51 has shown preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1a and CDK9. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Liposarcoma.

Liposarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Liposarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Liposarcoma

• There are approx. 15+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.

Phases

The report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Liposarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Liposarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Liposarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liposarcoma drugs.

Liposarcoma Report Insights

• Liposarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Liposarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Liposarcoma drugs?
• How many Liposarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Liposarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Liposarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Liposarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim
• Ascentage Pharma Group Inc.

Edgewood Oncology Inc.

Shanghai Pharmaceuticals Holding Co., Ltd

• Salarius Pharmaceuticals, LLC
• Lamassu Bio Inc
• Pfizer
• Valo Therapeutics Oy
• OncoResponse, Inc.

Adaptimmune

• Incyte Corporation
• Daiichi Sankyo
• Numab Therapeutics AG
• HRYZ Biotech Co.

Sotio Biotech Inc.

Key Products

• Brigimadlin
• APG-115
• BTX-A51
• SPH4336
• Seclidemstat
• SA53-OS
• PF-07220060
• PeptiCRAd-1
• OR2805
• Letetresgene autoleucel
• INCMGA00012
• DS-2243a
• NM32-2668
• MASCT-I
• CAR-GPC3 T Cells

This product will be delivered within 1-3 business days.